Literature DB >> 12694868

Two-step formation of 1H NMR visible mobile lipids during apoptosis of paclitaxel-treated K562 cells.

Fabrizia Brisdelli1, Egidio Iorio, Arno Knijn, Amalia Ferretti, Donatella Marcheggiani, Luisa Lenti, Roberto Strom, Franca Podo, Argante Bozzi.   

Abstract

Despite increasing evidence on the formation of 1H NMR-detectable mobile lipid (ML) domains in cells induced to programmed cell death by continuous exposure to anticancer drugs, the time course of ML generation during the apoptotic cascade has not yet been fully elucidated. The present study shows that ML formation occurs at two different stages of apoptosis induced in human erythroleukemia K562 cells by a brief (3 hr) exposure to paclitaxel (Taxol), an antitumour drug with a stabilising effect on microtubules, or to paclitaxel plus tyrphostin AG957, a selective inhibitor of the p210(BCR-ABL) tyrosine kinase activity. A first wave of ML generation was in fact detected in paclitaxel-treated cells at the onset of the effector phase (8-24hr after exposure to the drug), plateaued at 24-48 hr and was eventually followed by further ML accumulation during the degradative phase (48-72 hr). Addition of AG957 to paclitaxel shifted to the 3-8 hr interval in both the early ML production and the onset of apoptotic events, such as chromatin condensation, phosphatidylserine externalization, cytochrome c release and caspase-3 activation. A significant loss of mitochondrial membrane potential was almost concomitant with the second wave of ML accumulation, associated in both cell systems with the phase of terminal cell degeneration, likely connected to non-regulated degradation of cell lipid components.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12694868     DOI: 10.1016/s0006-2952(03)00080-7

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  6 in total

Review 1.  Apoptosis-detecting radioligands: current state of the art and future perspectives.

Authors:  Christophe M M Lahorte; Jean-Luc Vanderheyden; Neil Steinmetz; Christophe Van de Wiele; Rudi A Dierckx; Guido Slegers
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-05-12       Impact factor: 9.236

Review 2.  MR-visible lipids and the tumor microenvironment.

Authors:  E James Delikatny; Sanjeev Chawla; Daniel-Joseph Leung; Harish Poptani
Journal:  NMR Biomed       Date:  2011-04-27       Impact factor: 4.044

3.  1H NMR detection of mobile lipids as a marker for apoptosis: the case of anticancer drug-loaded liposomes and polymeric micelles.

Authors:  T Musacchio; M Toniutti; R Kautz; V P Torchilin
Journal:  Mol Pharm       Date:  2009 Nov-Dec       Impact factor: 4.939

4.  1H HR-MAS NMR Based Metabolic Profiling of Cells in Response to Treatment with a Hexacationic Ruthenium Metallaprism as Potential Anticancer Drug.

Authors:  Martina Vermathen; Lydia E H Paul; Gaëlle Diserens; Peter Vermathen; Julien Furrer
Journal:  PLoS One       Date:  2015-05-29       Impact factor: 3.240

5.  Synergistic effects of secretory phospholipase A2 from the venom of Agkistrodon piscivorus piscivorus with cancer chemotherapeutic agents.

Authors:  Jennifer Nelson; Kristen Barlow; D Olin Beck; Amanda Berbert; Nathan Eshenroder; Lyndee Francom; Mark Pruitt; Kina Thompson; Kyle Thompson; Brian Thurber; Celestine H-Y Yeung; Allan M Judd; John D Bell
Journal:  Biomed Res Int       Date:  2012-12-27       Impact factor: 3.411

6.  N-(4-iodophenyl)-N'-(2-chloroethyl)urea as a microtubule disrupter: in vitro and in vivo profiling of antitumoral activity on CT-26 murine colon carcinoma cell line cultured and grafted to mice.

Authors:  M Borel; F Degoul; Y Communal; E Mounetou; B Bouchon; R C-Gaudreault; J C Madelmont; E Miot-Noirault
Journal:  Br J Cancer       Date:  2007-05-08       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.